FGP
IRON icon

Freestone Grove Partners’s Disc Medicine IRON Stock Holding History

Freestone Grove Partners’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,687
Closed -$4.39M – 1177
2026
Q1 		$4.39M Buy
+68,687
New +$4.77M 0.03% 331

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Freestone Grove Partners's IRON Position: Q2 2026 in Review

Freestone Grove Partners sold out of Disc Medicine (IRON) in Q2 2026, closing a stake of 68,687 shares — an estimated $4.39M sold.

Freestone Grove Partners first reported a position in IRON in Q1 2026 and held it in 1 quarter. The position peaked at $4.39M in Q1 2026. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Freestone Grove Partners reported no remaining Disc Medicine position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 68,687 Disc Medicine shares in Q2 2026, an estimated $4.39M.
  • Freestone Grove Partners first reported a position in Disc Medicine in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Disc Medicine position peaked at $4.39M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.